GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diaceutics PLC (LSE:DXRX) » Definitions » Research & Development

Diaceutics (LSE:DXRX) Research & Development : £0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Diaceutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Diaceutics's Research & Development for the six months ended in Dec. 2024 was £0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was £0.00 Mil.

Diaceutics Research & Development Historical Data

The historical data trend for Diaceutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diaceutics Research & Development Chart

Diaceutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only - - - - -

Diaceutics Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Diaceutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diaceutics  (LSE:DXRX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Diaceutics Research & Development Related Terms

Thank you for viewing the detailed overview of Diaceutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Diaceutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diaceutics PLC (LSE:DXRX) » Definitions » Research & Development
Comparable Companies
LSE:KOO LSE:OPT LSE:RENX LSE:COG LSE:INHC LSE:FDBK LSE:TRLS LSE:IQAI AQSE:DXSP VEEV GEHC ASX:PME DOCS TEM TSE:2413 HQY WAY HKSE:02587 BTSG NSE:IKS
Traded in Other Exchanges
7DC:Germany
Address
Kings Hall Health and Wellbeing Park, Dataworks, First Floor, Building Two, Antrim, Belfast, GBR, BT9 6GW
Website
https://www.diaceutics.com
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides the pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine, enabled by DXRX The Diagnostic Network. DXRX is the diagnostic commercialization platform designed specifically for precision medicine, integrating multiple pipelines of real-world, real-time diagnostic testing data from a network of labs. These solutions are helping the pharma companies commercialize their precision medicines, enhance their return on investment and ultimately improve patients' lives.

Diaceutics Headlines

No Headlines